James Moy to Antibodies, Viral
This is a "connection" page, showing publications James Moy has written about Antibodies, Viral.
Connection Strength
1.523
-
SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine. JAMA Netw Open. 2021 08 02; 4(8):e2119741.
Score: 0.795
-
Longitudinal Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Antibody Responses and Identification of Vaccine Breakthrough Infections Among Healthcare Workers Using Nucleocapsid Immunoglobulin G. J Infect Dis. 2022 Nov 28; 226(11):1934-1942.
Score: 0.218
-
Neutralizing Antibody Activity to Severe Acute Respiratory Syndrome Coronavirus 2 Delta (B.1.617.2) and Omicron (B.1.1.529) After 1 or 2 Doses of BNT162b2 Vaccine in Infection-Naive and Previously Infected Individuals. J Infect Dis. 2022 10 17; 226(8):1407-1411.
Score: 0.216
-
COVID-19 Severity Is Associated with Differential Antibody Fc-Mediated Innate Immune Functions. mBio. 2021 04 20; 12(2).
Score: 0.195
-
Detection of SARS-CoV-2 variants by Abbott molecular, antigen, and serological tests. J Clin Virol. 2022 02; 147:105080.
Score: 0.051
-
Expanding access to SARS-CoV-2 IgG and IgM serologic testing using fingerstick whole blood, plasma, and rapid lateral flow assays. J Clin Virol. 2021 08; 141:104855.
Score: 0.049